Paper41008331
Botulinum Toxin: An Unconventional Tool for the Treatment of Depression?
Gambini M and 6 others. Brain Sci, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Botulinum Toxin: An Unconventional Tool for the Treatment of Depression? Papers, record 41008331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41008331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References112
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26996601 | Limbic Activity Modulation Guided by Functional Magnetic Resonance Imaging-Inspired Electroencephalography Improves Implicit Emotion Regulation. | Biol Psychiatry | 2016 | https://conductscience.org/library/papers/26996601 | PubMed |
| 2 | 30971906 | Amygdala Modulation During Emotion Regulation Training With fMRI-Based Neurofeedback. | Front Hum Neurosci | 2019 | https://conductscience.org/library/papers/30971906 | PubMed |
| 3 | 36991143 | Effects of glabellar botulinum toxin injections on resting-state functional connectivity in borderline personality disorder. | Eur Arch Psychiatry Clin Neurosci | 2024 | https://conductscience.org/library/papers/36991143 | PubMed |
| 4 | 39739012 | Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials. | Neuropsychopharmacology | 2025 | https://conductscience.org/library/papers/39739012 | PubMed |
| 5 | 37368686 | Botulinum Toxin Therapy for Psychiatric Disorders in Clinical Practice: A Retrospective Case Study. | Toxins (Basel) | 2023 | https://conductscience.org/library/papers/37368686 | PubMed |
| 6 | 36884287 | The integrated brain network that controls respiration. | Elife | 2023 | https://conductscience.org/library/papers/36884287 | PubMed |
| 7 | 29111119 | Direct central nervous system effects of botulinum neurotoxin. | Toxicon | 2018 | https://conductscience.org/library/papers/29111119 | PubMed |
| 8 | 7901002 | Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. | EMBO J | 1993 | https://conductscience.org/library/papers/7901002 | PubMed |
| 9 | 21877763 | Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. | Am J Clin Dermatol | 2011 | https://conductscience.org/library/papers/21877763 | PubMed |
| 10 | 33967844 | Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective. | Front Psychiatry | 2021 | https://conductscience.org/library/papers/33967844 | PubMed |
| 11 | 31638723 | Defining treatment-resistant depression. | Depress Anxiety | 2020 | https://conductscience.org/library/papers/31638723 | PubMed |
| 12 | 1257786 | Facial muscle patterning to affective imagery in depressed and nondepressed subjects. | Science | 1976 | https://conductscience.org/library/papers/1257786 | PubMed |
| 13 | 34423572 | The safety and efficacy of botulinum toxin A on the treatment of depression. | Brain Behav | 2021 | https://conductscience.org/library/papers/34423572 | PubMed |
| 14 | 37244542 | Association between depression and oxidative balance score: National Health and Nutrition Examination Survey (NHANES) 2005-2018. | J Affect Disord | 2023 | https://conductscience.org/library/papers/37244542 | PubMed |
| 15 | 37235370 | Botulinum Toxin Treatment for Depression: A New Paradigm for Psychiatry. | Toxins (Basel) | 2023 | https://conductscience.org/library/papers/37235370 | PubMed |
| 16 | 20548056 | Cosmetic use of botulinum toxin-a affects processing of emotional language. | Psychol Sci | 2010 | https://conductscience.org/library/papers/20548056 | PubMed |
| 17 | 40226647 | OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study). | Depress Anxiety | 2024 | https://conductscience.org/library/papers/40226647 | PubMed |
| 18 | 16426085 | Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. | J Clin Psychiatry | 2006 | https://conductscience.org/library/papers/16426085 | PubMed |
| 19 | 30587995 | Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm. | Neuropsychiatr Dis Treat | 2019 | https://conductscience.org/library/papers/30587995 | PubMed |
| 20 | 40142828 | Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights. | J Clin Med | 2025 | https://conductscience.org/library/papers/40142828 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42352619 | From Resistance to Redesign-The Emerging Logic of Hybrid Care in Treatment-Resistant Depression. | Brain Sci | 2026 | https://conductscience.org/library/papers/42352619 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| BDNF | 627 | PubTator's text mining | https://conductscience.org/library/genes/627 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41008331
GET https://conductscience.org/api/papers/v1/41008331/references?page=2